Antiretroviral therapies in women after single-dose nevirapine exposure.

ABSTRACT:

Background

Peripartum administration of single-dose nevirapine reduces mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) but selects for nevirapine-resistant virus.

Methods

In seven African countries, women infected with HIV-1 whose CD4+ T-cell counts were below 200 per cubic millimeter and who either had or had not taken single-dose nevirapine at least 6 months before enrollment were randomly assigned to receive antiretroviral therapy with tenofovir–emtricitabine plus nevirapine or tenofovir-emtricitabine plus lopinavir boosted by a low dose of ritonavir. The primary end point was the time to confirmed virologic failure or death.

Results

A total of 241 women who had been exposed to single-dose nevirapine began the study treatments (121 recei

SUBMITTER: Lockman S 

PROVIDER: S-EPMC2994321 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature